LAVAL, Quebec–(BUSINESS WIRE)–In connection with its previously announced public offering of common shares in Canada and the United States (the “Offer”), BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU) today announced that it has entered into a bought deal agreement with Jefferies, Evercore ISI and RBC Capital Markets as joint bookrunners and LifeSci Capital as lead manager (collectively, the “Subscribers”), in connection with the public offering of 16,540,541 common shares. The shares are being sold at a public offering price of US$9.25 per common share. The offering is expected to close on July 18, 2022, subject to the satisfaction of customary closing conditions. In addition, the underwriters have been granted an option within 30 days following the date hereof to purchase up to 2,481,081 additional common shares of the Company.
The Offering is being made in Canada pursuant to a prospectus supplement (the “Supplement”) to the amended and restated short form base shelf prospectus of the Company dated December 14, 2021 amending and restating the short form base shelf prospectus of the Company dated December 23, 2020 (the “A&R Base Shelf Prospectus”) and in the United States pursuant to a registration statement on Form F-10, as may be amended from time to time, containing the Supplement and the A&R Base Shelf Prospectus filed with the United States Securities and Exchange. Commission (the “SEC”) pursuant to the multi-jurisdictional disclosure system established between Canada and the United States.
The Company intends to use the net proceeds of the Offering primarily to fund BLU-5937 research and development activities, working capital requirements and other general corporate purposes, as indicated in the Supplement.
The common shares of the Company are listed on the Toronto Stock Exchange (the “TSX”) and the Nasdaq Global Market (“Nasdaq”) under the symbol “BLU”. For purposes of TSX approval, the Company intends to rely on the exemption set out in Section 602.1 of the TSX Company Manual, which provides that the TSX will not enforce its standards to certain transactions involving eligible interlisted issuers on a recognized stock exchange, such as Nasdaq.
The Supplement and the accompanying A&R Base Shelf Prospectus contain important detailed information about the Offering. The Supplement and the accompanying A&R Base Shelf Prospectus may be viewed on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. Copies of the Supplement and the accompanying A&R Base Shelf Prospectus may also be obtained from the Company, by telephone at 450-680-4500 or by email at email@example.com or you may request them from, in the States States, of Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by phone at 877-821-7388 or by email at firstname.lastname@example.org, or Evercore Group LLC , Attn: Equity Capital Markets, 55 East 52n/a Street, 35e Floor, New York, NY 10055, by phone at 888-474-0200 or by email at email@example.com, or RBC Capital Markets, LLC, Attention: Equity Capital Markets, 200 Vesey Street, 8th Floor, New York , NY 10281, by phone at 877-822-4089 or by email at firstname.lastname@example.org or, in Canada, Jefferies Securities, Inc., Attention: General Counsel, 161 Bay Street, Suite 2600, Toronto, ON M5J 2S1 by email email@example.com, or RBC Dominion Securities Inc., c/o Distribution Centre, 180 Wellington Street West, 8th Floor, Toronto, ON M5J 0C2, by phone 1-416-842-5349 or by email to Distribution. RBCDS@rbccm.com. Prospective investors should read the Supplement and the accompanying A&R Base Shelf Prospectus and other documents filed by the Company before making an investment decision.
No regulatory authority has approved or disapproved of the contents of this press release. This press release does not constitute an offer to sell or the solicitation of an offer to buy, and there will be no sale of these securities in any province, state or jurisdiction in which such offer, solicitation or sale would be illegal prior to registration. or qualification under the securities laws of any such province, state or jurisdiction.
About BELLUS Health
BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other hypersensitivity-related disorders. The Company’s product candidate, BLU-5937, is being developed for the treatment of adults with RCC.
Caution Regarding Forward-Looking Statements
Certain statements contained in this press release, other than independently verifiable statements of fact as of the date hereof, may constitute “forward-looking statements” within the meaning of Canadian securities laws and regulations, the US Private Securities Litigation Reform Act of 1995, as amended, and other applicable securities laws. Such statements, based on management’s current expectations, inherently involve numerous important known and unknown risks, uncertainties and assumptions. In this press release, such forward-looking statements include, but are not limited to, statements regarding the offer, the grant of the option to purchase additional shares and the intended use of the proceeds of the offer. . Completion of the Offer is subject to numerous factors, many of which are beyond BELLUS Heath’s control, including, but not limited to, market conditions, the parties’ failure to satisfy certain closing and other important factors disclosed previously and from time to time in BELLUS Health’s filings with the securities regulatory authorities in each of the provinces of Canada and the SEC. Actual future events may differ from the anticipated events expressed in these forward-looking statements. BELLUS Health believes that the expectations represented by the forward-looking statements are reasonable, but there can be no assurance that such expectations will prove to be correct. The reader should not place undue reliance, if any, on the forward-looking statements included in this press release. These forward-looking statements speak only as of the date they are made, and BELLUS Health is under no obligation and disclaims any intention to publicly update or revise these statements as a result of any new information, future events , circumstances or otherwise, unless required by the applicable provisions. securities laws.